Chief Business Officer · Altimmune, Inc. (ALT)

Raymond Jordt

FY2023 is the first fiscal year CompBrief holds for Raymond Jordt as a named executive officer of Altimmune; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,940,984

Salary $405,000Stock awards $586,125

2nd of 3 named executive officers at Altimmune by FY2023 total.

3 named officers on file for Altimmune, FY2023

Raymond Jordt’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ALT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Altimmune’s whole pay program stands against its peers

  • Altimmune’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 15, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Raymond Jordt’s full pay file as a PDF — free

More than this page: up to 10 years of Raymond’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Raymond Jordt compensation by year

Altimmune Summary Compensation Table · the one fiscal year held
In US dollars, as Altimmune reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$405,000
Bonus$0
Stock awards$586,125
Option awards$1,776,009
Non-equity incentive$162,000
Pension and deferred compensation$0
All other$11,850
Total$2,940,984

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Altimmune, Inc. DEF 14A filed August 15, 2024, accession 0001326190-24-000038, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Altimmune, Inc. filed document, accession 0001326190-24-000038. Every figure is read from that document and cited to the page and table it appears in. Filed August 15, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU37,500$421,875—
Option125,000—$15.63

Per the Outstanding Equity Awards at Fiscal Year-End table in Altimmune, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

20 Form 4 lines since the FY2023 proxy (filed August 15, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-31Grant or award—4,571$3.0770,107
2026-01-27Exercise or conversion derivative—15,850$0.0047,550
2026-01-27Tax withholding—4,229$6.1865,536
2026-01-27Exercise or conversion—15,850$0.0069,765
2026-01-25Tax withholding—3,855$5.5053,915
2026-01-25Exercise or conversion derivative—14,600$0.0029,200
2026-01-25Exercise or conversion—14,600$0.0057,770
2026-01-01Tax withholding—2,475$3.6143,170

The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Altimmune’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Vipin GargChief Executive Officer$5,482,089
Raymond Jordt · this pageChief Business Officer$2,940,984
M. Scott HarrisChief Medical Officer$2,239,988

The full Altimmune compensation record

free company brief

This page is one person within Altimmune's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Altimmune's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Raymond Jordt's compensation dossier · One-time report. No refunds.